BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

LOTTE BIOLOGICS Expands Global CDMO Footprint with Antibody Therapeutics Deal with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and Europe LOTTE BIOLOGICS announced on June 19, 2025 that it ha...

June 19, 2025 | News

Veranova Invests Over $50M to Launch Bioconjugation Development and GMP Manufacturing in Massachusetts

Veranova, a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for the pha...

June 19, 2025 | News

Debiopharm and Alkyon Therapeutics Join Forces to Advance Precision Radioligand Cancer Therapies

Research program combining Debiopharm’s AbYlink™ conjugation technology with Alkyon’s modular antibody platform and novel targeting app...

June 16, 2025 | News

Kelun-Biotech’s TROP2 ADC and PD-L1 Combo Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab ti...

June 12, 2025 | News

Sanyou Biopharmaceuticals and Medicovestor Forge Strategic Partnership to Advance First-in-Class Chemoimmunotherapy ADCs

Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D announced the signing ...

June 11, 2025 | News

Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

June 05, 2025 | News

China Approves First Homegrown ADC, Trastuzumab Rezetecan, for HER2-Mutant Lung Cancer

The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically develo...

May 30, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Avenzo Therapeutics and Duality Biotherapeutics Gain FDA Clearance for EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-gen...

May 26, 2025 | News

DualityBio and Avenzo Receive FDA IND Clearance for Novel EGFR/HER3 Bispecific ADC

Duality Biotherapeutics partner Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced c...

May 23, 2025 | News

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

Fujifilm Validates Cancer-Targeting Potential of Peptide-Oligonucleotide Conjugates Using Proprietary Cyclic Peptide Library

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation ...

May 21, 2025 | News

Minghui Pharma Licenses B7-H3 ADC MHB088C to Qilu for Greater China in RMB 1.345 Billion Deal

Minghui Pharmaceutical , a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Phar...

May 12, 2025 | News

Stay Connected